Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By BMS Drug

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA has dealt a setback to Eisai's burgeoning oncology pipeline by denying the company's efforts to seek accelerated approval for its microtubule growth suppressor E7389 (eribulin mesylate)
Advertisement

Related Content

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
Eisai's Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson's Disease
Advertisement
UsernamePublicRestriction

Register

SC067609

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel